The EGF Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte cell line. This product provides a loss-of-function model for the EGF gene, enabling targeted disruption of EGF-mediated signaling without the need for clonal isolation. As a polyclonal population, it reflects the heterogeneous editing outcomes typically obtained following CRISPR/Cas9 delivery and selection, making it suitable for pooled screening and population-level functional analyses. The polyclonal format allows researchers to study averaged phenotypic effects across a genetically diverse knockout background, which can be particularly advantageous for assays where clonal variation may confound results.
The Raji cell line originates from a human Burkitt lymphoma, an aggressive B-cell malignancy, and is Epstein-Barr virus (EBV)-positive. Raji cells are widely used as a model for B lymphocyte biology, including studies of immune response and antibody production. Their lymphoblastoid nature and expression of surface markers such as CD20 make them a valuable system for investigating B-cell receptor signaling, lymphomagenesis, and therapeutic antibody mechanisms. The EBV positivity additionally provides a context for studying virus?Chost interactions and their impact on B-cell transformation.
EGF binds EGFR, triggering receptor dimerization and autophosphorylation, which recruits GRB2 and SOS to activate RAS. This initiates the RAF?CMEK?CERK cascade, while PI3K activates AKT and mTOR, and JAK/STAT signaling is also engaged. These pathways converge on transcription factors like FOS, JUN, and MYC, upregulating CCND1, BCL2, MMP9, and VEGF. Key upstream regulators include STAT3, ??-catenin, SP1, AP-1, hypoxia, and TGF??; signaling is further modulated through dimerization with ERBB2 and ERBB4.
In Raji B lymphocytes, the role of EGF/EGFR signaling is less defined than in epithelial systems, yet EGFR expression on B cells suggests involvement in immune responses and lymphoproliferation. Disruption of EGF in this polyclonal knockout population eliminates autocrine/paracrine ligand stimulation, thereby quenching downstream mitogenic and survival signals. This model facilitates the dissection of EGF-dependent pathways in B-cell lymphoma, including potential crosstalk with B-cell receptor or EBV latent programs, and enables evaluation of lymphoma cell dependence on this growth factor axis.
Researchers can utilize this polyclonal knockout cell pool in functional genomics screens to uncover synthetic lethal interactions, drug discovery assays targeting EGFR or downstream kinases, and detailed signaling studies using phospho-specific flow cytometry or Western blotting. It is applicable in ADCC assays to assess how EGF loss influences target cell sensitivity to therapeutic antibodies. Proliferation assays and RT-qPCR enable validation of EGF disruption effects on cell growth and gene expression, offering insights into EGF-dependent vulnerabilities in lymphoma. For further information or assistance with assay optimization, please contact Ascent Research.
